Microbicide vaginal gel containing C2F5/C4E10/C2G12 MAbs for HIV-1 is safe in phase I trial March 9, 2011
Ganetespib is active in NSCLC and set to enter phase IIb/III trial in combination with docetaxel March 4, 2011
Germline SNPs inked to outcome of docetaxel-treated metastatic castration-resistant prostate cancer March 2, 2011
RSS